-
公开(公告)号：US12064507B2
公开(公告)日：2024-08-20
申请号：US17232393
申请日：2021-04-16
Applicant: Provectus Pharmatech, Inc. , UTI Limited Partnership
Inventor： Aru Narendran , Dominic Rodrigues , Bruce Horowitz , Edward V. Pershing , Eric A. Wachter
CPC classification number: A61K9/0019 , A61K9/0053 , A61K31/352 , A61K45/06 , A61P35/02 , A61K9/08 , A61K9/167
Abstract: A method of treating a mammalian subject having hematologic, non-tumorous cancer cells is disclosed. The method comprises the steps of: (A) administering to such a mammalian subject a therapeutically effective amount of a halogenated xanthene, a pharmaceutically acceptable salt or a C1-C4 alkyl ester thereof as a first cancer cytotoxic agent dissolved or dispersed in a pharmaceutically acceptable aqueous medium. The mammalian subject is maintained for a period of time sufficient to induce death of hematologic, non-tumorous cancer cells. A contemplated administration is typically repeated. A contemplated treatment method can also be carried out in conjunction with administration to said mammalian subject of a second therapeutically effective amount of a second, differently-acting cancer cytotoxic agent dissolved or dispersed in a pharmaceutically acceptable medium. The second cancer cytotoxic agent can be a small molecule or an intact antibody or paratope-containing portion thereof.
-
公开(公告)号：US20240181049A1
公开(公告)日：2024-06-06
申请号：US17773129
申请日：2020-11-02
Applicant: UTI LIMITED PARTNERSHIP
Inventor： Kathleen Dora MCCOY , Lukas Franz MAGER
IPC: A61K39/395 , A61K31/708 , A61K35/00 , A61K35/741 , A61K35/745 , A61K35/747 , A61P35/00 , C12N1/20 , C12R1/01 , C12R1/225
CPC classification number: A61K39/3955 , A61K31/708 , A61K35/741 , A61K35/745 , A61K35/747 , A61P35/00 , C12N1/205 , A61K2035/115 , C12R2001/01 , C12R2001/225
Abstract: Disclosed is a method for treatment of a subject having, or suspected of having, a cancer, in particular colorectal cancer, using an immune checkpoint inhibitor in combination with one or more bacteria selected from Bifidobacterium pseudolongum, Lactobacillus johnsonii, and Olsenella species, wherein the immune checkpoint inhibitor is an anti-CTLA-4 antibody or an anti-PD-1 antibody, wherein antibiotic therapy may precede the use of the immune checkpoint inhibitor and the one or more bacteria.
-
公开(公告)号：US20240101664A1
公开(公告)日：2024-03-28
申请号：US18257107
申请日：2021-12-14
Applicant: UTI LIMITED PARTNERSHIP
Inventor： Joel S. ZINDEL , Paul KUBES
CPC classification number: C07K16/28 , A61P41/00 , A61K2039/505 , C07K2317/76
Abstract: The present disclosure relates generally to treatment of peritoneal, pleural, and pericardium adhesions.
-
公开(公告)号：US11837962B2
公开(公告)日：2023-12-05
申请号：US17363848
申请日：2021-06-30
Applicant: UTI LIMITED PARTNERSHIP
Inventor： Iman Askarianabayaneh , Majid Pahlevaninezhad , Andrew Michael Knight
CPC classification number: H02M3/33584 , H02M1/0058
Abstract: Control system and method for controlling power flow in dual active bridge converters. The control system comprises a compensator, a feedback unit, and a modulator. An outer loop provides a reference signal. The output of the compensator are the control parameters for the modulator. The feedback unit samples the transformer current once every half switching cycle to thereby determine a power level. The power level is used to determine a modulation technique to apply. The modulation technique is one of phase-shift modulation (PSM), variable duty cycle modulation (VDM), or triangular current mode modulation (TCM).
-
公开(公告)号：US11754590B2
公开(公告)日：2023-09-12
申请号：US17298647
申请日：2020-01-24
Applicant: UTI LIMITED PARTNERSHIP
Inventor： Ahmed Youssef , Naser El-Sheimy
IPC: G01P15/093 , G01P15/03 , G01P15/18 , G01P15/00
CPC classification number: G01P15/093 , G01P15/006 , G01P15/032 , G01P15/038 , G01P15/18
Abstract: Systems and methods relating to sensors for measuring acceleration. Two attached containers are each filled with different liquids. At each junction of the two liquids, an indicator is placed. When acceleration forces are applied to the sensor, the indicator moves when the boundary between the two liquids similarly move. The amount of movement of the boundary and of the indicator is proportional to the amount of acceleration for applied. A tracking subsystem tracks the position of the indicator and, by determining the amount of movement of the indicator, the amount of acceleration force applied can be calculated. The indicator can be a particle or it can be a beam-like element that deflects when the boundary between the two liquids move.
-
Patent Agency Ranking
公开(公告)号：US11717580B2
公开(公告)日：2023-08-08
申请号：US17053146
申请日：2019-05-07
Inventor： Chang-Chun Ling , Pier-Luc Champagne , Ping Zhang , Géraldine Gouhier
IPC: A61K49/12 , A61K49/08 , C02F101/20 , C02F1/68 , C02F101/00
CPC classification number: A61K49/124 , A61K49/085 , A61K49/122 , C02F1/683 , C02F2101/006 , C02F2101/20
Abstract: Compounds are described which include polyvalent ligands linked to a cyclodextrin scaffold which exhibit strong binding affinities for lanthanides and favorable characteristics with respect to altering the relaxation time of coordinated water molecules. The compounds are useful as contrast agents in applications such as magnetic resonance imaging. The polyvalent ligands are also useful in applications requiring chelation of metal ions in other applications such as water treatment, sequestration of metal ions and treatment of diseases or conditions caused by exposure to toxic or radioactive metal ions.
-
公开(公告)号：US11623862B2
公开(公告)日：2023-04-11
申请号：US17068372
申请日：2020-10-12
Applicant: UTI Limited Partnership
IPC: C01B3/34 , C01B3/02 , C07C29/151 , C07C41/01
Abstract: A process for producing syngas including at least H2 and CO. The process includes the steps of a) generating a transition metal carbide by reacting a corresponding transition metal oxide with a fuel to produce a stream of syngas; and b) combining the transition metal carbide with oxygen to oxidize the transition metal carbide to regenerate the corresponding transition metal oxide, thereby producing a gas output comprising at least one or more oxidized carbon compounds and heat for autothermal operation.
-
公开(公告)号：US11559219B2
公开(公告)日：2023-01-24
申请号：US16376603
申请日：2019-04-05
Applicant: UTI Limited Partnership
Inventor： Abdulwadood Abdullah Al-Ali , Brent Maundy , Ahmed Elwakil
Abstract: Systems and methods relating to bio-impedance analysis. The system eliminates the need for hardware phase measurements by using the K-K transform to extract the phase from the magnitude detected. The system has a magnitude detection sub-system that includes a signal generation block, a DC cancellation block, and an amplitude control block. An A/D converter converts the detected magnitude into a digital signal and signal processing is performed to extract the phase of the signal from the magnitude detected.
-
公开(公告)号：US20220387583A1
公开(公告)日：2022-12-08
申请号：US17651664
申请日：2022-02-18
Applicant: UTI Limited Partnership
Inventor： Pedro SANTAMARIA
IPC: A61K39/385 , C07K14/74 , A61K47/69
Abstract: Provided are peptide-MHC class I and class II molecules having improved stability and high potency, and that can be produced in high yield. Also provided are receptor-signaling nanoparticles comprising the improved peptide-MHC molecules.
-
公开(公告)号：US11419844B2
公开(公告)日：2022-08-23
申请号：US16688319
申请日：2019-11-19
Applicant: Provectus Pharmatech, Inc. , UTI Limited Partnership
Inventor： Eric A. Wachter , Dominic Rodrigues , Satbir Thakur , Lucy Swift , Chunfen Zhang , Mohit Jain , Aru Narendran
IPC: A61K31/352 , A61P35/00 , C07K16/28
Abstract: A method of treating a mammalian subject having hematologic, non-tumorous cancer cells is disclosed. The method comprises the steps of: (A) administering to such a mammalian subject a therapeutically effective amount of a halogenated xanthene, a pharmaceutically acceptable salt or a C1-C4 alkyl ester thereof as a first cancer cytotoxic agent dissolved or dispersed in a pharmaceutically acceptable aqueous medium. The mammalian subject is maintained for a period of time sufficient to induce death of hematologic, non-tumorous cancer cells. A contemplated administration is typically repeated. A contemplated treatment method can also be carried out in conjunction with administration to said mammalian subject of a second therapeutically effective amount of a second, differently-acting cancer cytotoxic agent dissolved or dispersed in a pharmaceutically acceptable medium. The second cancer cytotoxic agent can be a small molecule or an intact antibody or paratope-containing portion thereof.
-
-
-
-
-
-
-
-
-
Search Results
271
records
(took 0.023 seconds)
